Intercept Beats Investor Suit Over Liver Disease Drug Deaths
Intercept Pharmaceuticals Inc. on Thursday exited a proposed securities class action accusing it of covering up reports of fatalities and injuries caused by a liver disease drug, after a New York...To view the full article, register now.
Already a subscriber? Click here to view full article